YY1 and neoplasm: Moreover, GEM-based treatment resulted in an objective response rate (ORR) of 16.2% and a disease control rate (DCR) of 62.2%; high miR-135b/low BMAL1/high YY1 expression facilitated GEM resistance, whereas those patients with low miR-135b/high BMAL1/low YY1-expressing tumours had relatively higher chemosensitivity (Supplementary Table S10).